Chonluten Peptide 20mg

Description

What Is Chonluten Peptide?

Chonluten peptide is a synthetic tripeptide bioregulator with the amino acid sequence Glu-Asp-Gly (EDG), developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson bioregulator peptide program. Chonluten belongs to the class of short control peptides known as bioregulator peptides — low-cell-level-weight compounds that show tissue-specific gene expression tuning at natural levels. Chonluten’s target tissue is the bronchopulmonary system, where it has been studied for its capacity to restore normal gene expression patterns in respiratory epithelial cells and bronchial tissue in lab and clinical gerontology research models.

Unlike conventional pharmaceutical compounds that act through receptor agonism or enzyme blocking, Khavinson bioregulator peptides such as chonluten operate through direct interaction with specific DNA sequences in the promoter regions of target genes. This epigenetic mechanism of action — tuning transcription rather than blocking or starting receptors — represents a fundamentally different approach to tissue function restoration that has been the subject of over four decades of research at the St. Petersburg Institute. PrymaLab Chonluten 20mg is manufactured to high purity standards and supplied exclusively for qualified lab research uses.

Chonluten 20mg: Key Specifications

How Chonluten Works: Bioregulator Mechanism of Action

Chonluten operates through the Khavinson model of peptide bioregulation, in which short peptides (2–4 amino acids) interact with specific paired DNA sequences in gene promoter regions, tuning the transcription of genes key to tissue-specific function. This mechanism was first proposed by Khavinson and Anisimov in the early 2000s and has since been supported by cell-level biology studies showing direct peptide-DNA binding in cell-free and in vitro systems.

Epigenetic Gene Expression Modulation

Research published by the St. Petersburg Institute shows that chonluten selectively tunes the expression of genes involved in bronchopulmonary tissue homeostasis. In aged respiratory tissue models, chonluten can restore gene expression patterns toward profiles characteristic of younger tissue, suggesting a restorative rather than stimulatory mechanism. This epigenetic approach differentiates bioregulator peptides from growth factors or cytokines that directly boost cell proliferation, instead acting at the transcriptional control level to normalize tissue function.

Respiratory Tissue Specificity

Among the Khavinson bioregulator peptide family, chonluten shows preferential activity in bronchial and pulmonary tissue. Lab studies have examined chonluten’s effects on bronchial epithelial cell gene expression, mucin production control, anti-swelling cytokine tuning, and respiratory epithelial barrier integrity. The tissue specificity of short bioregulator peptides is hypothesized to derive from the paired matching between the peptide’s amino acid sequence and specific DNA motifs enriched in the promoter regions of tissue-specific genes — a selectivity mechanism analogous to transcription factor-DNA recognition but operating through much smaller cell-level entities.

Chonluten Peptide Benefits: What Research Shows

The following research context reflects published lab and clinical gerontology literature from the Khavinson research program. PrymaLab Chonluten 20mg is supplied exclusively for research purposes and is not intended for treatment use.

Bronchopulmonary Function in Aging Models

Chonluten has been studied in gerontological models examining age-related decline in respiratory function. Khavinson’s research group reported that use of chonluten in aged animal models was linked with normalization of bronchial epithelial cell function, improved mucociliary clearance markers, and restoration of respiratory gene expression profiles toward patterns saw in younger animals. These findings position chonluten within the broader bioregulation hypothesis — that short peptides can restore tissue-specific gene expression patterns that deteriorate during natural aging.

Anti-inflammatory Respiratory Effects

Lab studies have examined chonluten’s effects on swelling signaling in bronchial tissue models. Research from the St. Petersburg Institute shows tuning of pro-swelling cytokine expression in respiratory epithelial cells, including effects on IL-6 and TNF-α pathways. These anti-swelling properties are consistent with the broader bioregulator hypothesis that peptide-mediated gene expression normalization reduces the chronic low-grade swelling (inflammaging) linked with tissue aging.

Respiratory Epithelial Barrier Integrity

The integrity of the respiratory epithelial barrier is key to lung defense against pathogens and environmental insults, and declines with natural aging. Chonluten research has examined its effects on tight junction protein expression and epithelial cell differentiation markers in bronchial tissue models, with published data suggesting improved barrier function parameters in aged tissue treated with the peptide.

Chonluten vs. Bronchogen: Respiratory Bioregulator Comparison

PrymaLab offers two Khavinson bioregulator peptides targeting the respiratory system. The following table summarizes the key distinctions for researchers selecting between them.

How to Store and Handle PrymaLab Chonluten 20mg

1. Store freeze-dried at −20°C. Keep the sealed vial in a dedicated laboratory freezer, desiccated and protected from light. Freeze-dried chonluten peptide is stable for 24+ months under these conditions.
2. Allow vial to reach room heat before opening. Removing a cold vial and immediately opening it can introduce condensation moisture that degrades the peptide.
3. Reconstitute with appropriate sterile solvent. Use sterile water, sterile saline, or another solvent appropriate for your research protocol. Add solvent slowly along the vial wall to avoid foaming.
4. Use mixed solution within 2–4 weeks. Store mixed peptide at 2–8°C. Mark the mixing date on the vial label.
5. Avoid repeated freeze-thaw cycles. If the full quantity will not be used in a single session, aliquot the mixed solution into single-use portions before freezing.
6. Retain the Certificate of Test. Record the lot number and keep the COA for the duration of your research for traceability and data integrity purposes.

Why Choose PrymaLab Chonluten 20mg?

PrymaLab supplies Chonluten 20mg as a high-purity research-grade bioregulator peptide verified by reverse-phase HPLC at ≥98% purity and identity-confirmed by mass spectrometry. Each production batch is assigned a unique lot number and accompanied by a Certificate of Test documenting purity, identity, and quality testing results. Testing is conducted by independent analytical laboratories to ensure unbiased results and full traceability. PrymaLab’s commitment to batch-level records supports the data integrity requirements of GLP-compliant research environments and peer-reviewed publication standards.

Frequently Asked Questions About Chonluten Peptide

What is chonluten and what class of compounds does it belong to?

Chonluten is a synthetic tripeptide with the sequence Glu-Asp-Gly (EDG) belonging to the Khavinson bioregulator peptide class. Bioregulator peptides are short (2–4 amino acid) compounds developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology that show tissue-specific gene expression tuning. Chonluten’s target tissue is the bronchopulmonary system, and it has been studied in lab and gerontological research models for over two decades.

What are the reported chonluten peptide benefits in research?

Published research from the Khavinson program reports that chonluten peptide benefits include normalization of respiratory gene expression patterns in aged tissue models, tuning of swelling cytokines in bronchial tissue, gain of mucociliary clearance markers, and restoration of respiratory epithelial barrier integrity. All reported benefits are from lab and gerontological research settings and do not represent treatment claims.

How does chonluten differ from bronchogen?

Both chonluten (EDG) and bronchogen (AED) are Khavinson respiratory bioregulator peptides, but they differ in amino acid sequence and research focus. Chonluten has been studied for broader bronchopulmonary gene expression tuning and anti-aging respiratory effects, while bronchogen targets bronchial mucosal repair and has been studied more mainly in chronic bronchitis and COPD research models. Some research protocols use both peptides together for full respiratory tissue support.

How should chonluten 20mg be stored?

Store freeze-dried chonluten at −20°C, desiccated and protected from light, where it is stable for 24+ months. After mixing with sterile solvent, store at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles. Aliquot mixed solution into single-use portions if the full quantity will not be used in one session.

What purity and testing standards does PrymaLab apply?

PrymaLab Chonluten 20mg is verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Test. All testing is conducted by independent analytical laboratories to ensure unbiased quality check and full supply chain traceability for research records purposes.

Research Disclaimer

For Research Use Only. PrymaLab Chonluten 20mg is intended exclusively for qualified lab research use by trained laboratory professionals. This product is not intended for human consumption, treatment use, veterinary treatment, or any use outside controlled research environments. Chonluten has not been approved by the FDA or any equivalent control authority for treatment use. All research uses described on this page are drawn from published lab and gerontological literature. Researchers are solely responsible for ensuring compliance with all applicable institutional and control requirements.